Reveal Genomics and Ona Therapeutics Partner to Advance Ona Therapeutics’ investigational drug, ONA-255, in Clinical Trials

Reveal Genomics and Ona Therapeutics are collaborating to accelerate the clinical development of ONA-255. The partnership aims to advance the drug through its clinical trial phases. The collaboration brings together Reveal Genomics’ expertise in cancer genomics and diagnostics with Ona Therapeutics’ focus on developing therapeutic antibodies against metastasis-driving targets. ONA-255 is Ona Therapeutics’ investigational drug. The companies will work together to streamline the clinical trial process for ONA-255, potentially leading to faster availability of the drug for patients if it proves successful.

Newsflash | Powered by GeneOnline AI
Date: April 15, 2025

Related posts:

Experts Urge Inclusion of Pets in Disease Surveillance Amid Rising H5N1 Cases in Cats Global Generic Drug Market Projected to Reach $1.3 Trillion by 2027, Driven by Demand in Developing Nations Generic Drug Makers Use Stability Testing in Freedom to Operate Analysis to Ensure Regulatory Compliance. Police at Greater Risk of Brain Trauma and PTSD

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後